About Edelris AS-MS Symposium 2025 edition
As part of Edelris’s 20th-anniversary celebrations, this symposium marked two decades of innovation in small-molecule drug discovery and highlighted recent advances in hit identification using AS-MS. It brought together leading voices from both academia and industry to share cutting-edge developments in tackling challenging drug targets.
Together with Christel Menet, Jacques Hamon, Maria Duca, and Stefan Knapp, I had the pleasure of opening the first session. Through our respective research journeys, we illustrated how the past 20 years have revolutionized the field of small-molecule discovery.
The second session was dedicated to AS-MS, featuring an impressive lineup of speakers: Wenqing Shui, Cameron Hanna, Sebastian Pomplun, Aled Edwards, and Fabrice Jourdan. This session highlighted the evolution and increasing maturity of AS-MS, demonstrating its pivotal role in modern drug discovery—from addressing historically intractable protein targets to facilitating high-throughput screening of peptides, macrocycles, and small-molecule modalities. It clearly positioned AS-MS as a robust and well-established technology for hit identification, strengthened by advances in automation, workflow integration, and broadening applicability.
It was an exceptional day, bringing together scientists from diverse organizations, biotech and pharmaceutical companies, academic institutions, and CROs. Thank you to everyone who shared this enriching experience, and we will look forward to seeing you at the 6th Edelris Symposium on AS-MS in 2026!
Didier Roche, CSO